Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00226421 · ClinicalTrials.gov registry record · Phase 3

Efficacy and Safety of Oxymorphone Extended Release in Opioid-Experienced Patients With Chronic Non-Malignant Pain

A Phase 3 study of Chronic Pain, sponsored by Endo Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
120
Enrollment target
20
Study locations

NCT00226421 is a Phase 3 study of Chronic Pain that has completed, run by Endo Pharmaceuticals. The registered enrollment target is 120 participants, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00226421, a Phase 3 study of Chronic Pain, has completed, sponsored by Endo Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
120 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the analgesic efficacy and safety of oxymorphone extended release in opioid-experienced patients with chronic low back pain.

Conditions Studied

Interventions

  • DRUG Oxymorphone Extended Release

Study Locations (20)

Florida

  • Radiant Research - Daytona Beach
  • University Clinical Research - DeLand
  • LCFP Inc. - Fort Myers
  • Century Clinical Research - Holly Hill
  • Ocala Rheumatology Research Center - Ocala
  • The Arthritis Center - Palm Harbor
  • Radiant Research - Pinellas Park
  • Park Place Therapeutic Center - Plantation

Arizona

  • Phoenix Center for Clinical Research - Phoenix
  • Arizona Research - Phoenix

Georgia

  • Comprehensive Neurology Specialists - Atlanta
  • Comprehensive Neuroscience - Atlanta

Missouri

  • Research Medical Center - Kansas City
  • Radiant Research - St Louis

Alabama

  • Southern Drug Research - Hueytown

Colorado

  • Express Care Clinical Research - Colorado Springs

Delaware

  • Glasgow Family Practice - Newark

Illinois

  • Pain Specialists of Greater Chicago - Burr Ridge

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2004-10
Est. Completion 2005-08
Phase Phase 3

Sponsor

Endo Pharmaceuticals

23 total trials

What the Registry Record Tells You About NCT00226421

The ClinicalTrials.gov registry entry for NCT00226421 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (84% lower). The listed sponsor is Endo Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Pain appearing as the primary indexed condition, and to 1 intervention - of which Oxymorphone Extended Release is the first listed.

NCT00226421 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, Arizona, Georgia.

Frequently Asked Questions

What is clinical trial NCT00226421 about?

NCT00226421 is a clinical study titled "Efficacy and Safety of Oxymorphone Extended Release in Opioid-Experienced Patients With Chronic Non-Malignant Pain". The purpose of this study is to evaluate the analgesic efficacy and safety of oxymorphone extended release in opioid-experienced patients with chronic low back pain.

What is the current status of trial NCT00226421?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2004-10. Estimated completion is 2005-08.

What conditions does trial NCT00226421 study?

This clinical trial studies the following conditions: Chronic Pain.

What interventions are being tested in trial NCT00226421?

The interventions under investigation include: Oxymorphone Extended Release (DRUG).

Who is sponsoring clinical trial NCT00226421?

This trial is sponsored by Endo Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00226421 being conducted?

This trial has 20 study locations across Alabama, Arizona, Colorado, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.